Chemotherapy-induced apoptosis in epithelial ovarian cancers

Obstet Gynecol. 1995 Jun;85(6):1007-10. doi: 10.1016/0029-7844(95)00058-y.

Abstract

Objective: To determine whether chemotherapy drugs elicit programmed cell death (apoptosis) in ovarian cancer cells.

Methods: Monolayers of immortalized ovarian cancer cell lines and primary ovarian cancer cells obtained from ascites were grown in the presence of cisplatin, 4-hydroxyperoxy-cyclophosphamide (the active metabolite of cyclophosphamide) or paclitaxel. Next, DNA was extracted from the cells and subjected to electrophoresis to determine if DNA laddering characteristic of apoptosis was present.

Results: In three of six immortalized cell lines (OVCA 420, 429, and 433), apoptosis was not seen in response to any of the three drugs. In contrast, in OVCAR-3 and OVCA 432, DNA laddering consistent with apoptosis was observed in response to all three drugs. In the DOV 13 cell line, apoptosis was seen only with 4-hydroxyperoxycyclophosphamide. Among three primary ovarian cancers, cisplatin elicited apoptosis in one case. Both cell lines with mutant p53 genes (OVCAR-3 and OVCA 432) underwent apoptosis in response to all three drugs, whereas among three cell lines known to have normal p53 genes, one underwent apoptosis in response to 4-hydroxyperoxycyclophosphamide and two were unaffected.

Conclusion: Ovarian cancer cell death in response to commonly used chemotherapeutic drugs involves the induction of a genetically programmed sequence of events (apoptosis) rather than simply necrosis.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Apoptosis / drug effects*
  • Apoptosis / genetics
  • Cisplatin / pharmacology*
  • Cyclophosphamide / analogs & derivatives*
  • Cyclophosphamide / pharmacology
  • DNA, Neoplasm / analysis
  • Female
  • Humans
  • Ovarian Neoplasms / genetics
  • Ovarian Neoplasms / pathology*
  • Paclitaxel / pharmacology*
  • Tumor Cells, Cultured

Substances

  • 4-hydroxyperoxycyclophosphamide
  • DNA, Neoplasm
  • Cyclophosphamide
  • Paclitaxel
  • Cisplatin